Gilead Sciences stock price target raised to $140 from $126 at BofA

Gilead Sciences (GILD) reported strong second-quarter results, with sales of approximately $7.1 billion and EPS around $2.00, primarily driven by its robust HIV portfolio which exceeded expectations and led to raised company guidance. This performance has prompted multiple analyst upgrades and price target increases, including BofA Securities raising its target to $140 from $126 with a Buy rating, citing GILD as a "beat and raise story" underpinned by its high-margin HIV business, despite a reduction in Veklury sales forecasts. The stock, already near its 52-week high, reflects sustained analyst confidence in its core pharmaceutical segments.

Analysis

Gilead Sciences (GILD) is demonstrating significant operational strength, primarily driven by its high-margin HIV franchise. The company's second-quarter results surpassed consensus expectations, with revenue of $7.08 billion and non-GAAP EPS of $2.01, fueled by the outperformance of its HIV drugs Biktarvy and Descovy. This core strength was substantial enough for management to raise its full-year guidance, even while concurrently reducing the sales forecast for its COVID treatment, Veklury, by $400 million, or 29%. This performance has triggered a wave of positive revisions from Wall Street, with BofA Securities raising its price target to $140, Morgan Stanley to $143, and Truist Securities upgrading the stock to a Buy. The investment thesis, as articulated by BofA, centers on a "beat and raise story" underpinned by the durable HIV business, with a new valuation multiple applied to forward 2026 earnings estimates. The company's fundamental health is further supported by a strong gross profit margin of 78.5% and a reliable capital return policy, evidenced by 10 consecutive years of dividend increases. The stock's 50.6% return over the past year, bringing it near its 52-week high, reflects that the market is actively pricing in this positive outlook.

Key Decisions for Investors

• The consistent outperformance of the core HIV segment, which is driving upward revisions in guidance and analyst price targets, supports a bullish outlook for the stock.
• Given the stock has already appreciated 50.6% over the past year and trades near its 52-week high, investors should be mindful that significant positive sentiment may already be priced in.
• Key risks to monitor are any potential deceleration in the HIV franchise, as the investment thesis is heavily reliant on its sustained growth to offset the known decline in Veklury sales.
• Investors should note that prominent analyst valuations are based on long-term earnings, such as BofA's target using 2026 estimates, suggesting the thesis is predicated on durable, multi-year performance rather than short-term gains.